Syros Pharmaceuticals, Inc.
SYRSDelisted Mar 10, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001556263
Syros Pharmaceuticals, Inc. was delisted on Mar 10, 2025; its insiders filed their last Form 4 on Dec 4, 2024; 44 institutions reported holding it in 13F filings for Q4 2024, worth $1.20M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Syros Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Syros Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Simonian Nancy A | Director | 4,000 | Dec 4, 2024 | 0 |
| Stephens Kristin | Chief Development Officer | 0 | Nov 20, 2024 | 0 |
| Roth David | Chief Medical Officer | 0 | Nov 20, 2024 | 0 |
| Quirk Gerald E | Chief Legal & Compliance Offic | 0 | Nov 20, 2024 | 0 |
| Chee Conley | President & CEO | 0 | Nov 20, 2024 | 0 |
| Haas Jason | Chief Financial Officer | 0 | Nov 20, 2024 | 0 |
| Akkaraju Srinivas | Director | 9,333 | Sep 18, 2024 | 0 |
| Young Richard A | Director | 10,667 | Sep 18, 2024 | 0 |
| Wirth Peter | Director | 16,000 | Jun 7, 2024 | 0 |
| Tyson Timothy | Director | 33,189 | Jun 7, 2024 | 0 |
| Fanucci Marsha | Director | 16,000 | Jun 7, 2024 | 0 |
| Dunsire Deborah | Director | 12,000 | Jun 7, 2024 | 0 |
| Oh Andrew M. | Director | 16,000 | Jun 7, 2024 | 0 |
| Eckhardt Sue Gail | Director | 16,000 | Jun 7, 2024 | 0 |
| Alles Mark J | Director | 3,666 | Sep 19, 2023 | 0 |
| Olson Eric R | Chief Scientific Officer | 6,661 | Jul 18, 2023 | 0 |
| Sharp Phillip A | Director | – | Jun 2, 2022 | 0 |
| Nashat Amir | Director | – | Jun 2, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 4, 2024 (view filing)5:00 PM ET | Dec 2 | 2 days | Simonian Nancy ADirector | SSale | −37.1K | $0.2702 | −$10.0K | −90.3%4.00K after | |
| Nov 27, 2024 (view filing)5:00 PM ET | Nov 25 | 2 days | Simonian Nancy ADirector | SSale | −134.7K | $0.2653 | −$35.7K | −76.6%41.1K after | |
| Nov 20, 2024 (view filing)5:00 PM ET | Nov 18 | 2 days | Stephens KristinChief Development Officer | SSale | −36.1K | $0.22 | −$7.95K | −100.0%0 after | |
| Nov 20, 2024 (view filing)5:00 PM ET | Nov 18 | 2 days | Roth DavidChief Medical Officer | SSale | −12.1K | $0.1969 | −$2.38K | −100.0%0 after | |
| Nov 20, 2024 (view filing)5:00 PM ET | Nov 19 | 1 day | Quirk Gerald EChief Legal & Compliance Offic | SSale | −46.7K | $0.2212 | −$10.3K | −100.0%0 after | |
| Nov 20, 2024 (view filing)5:00 PM ET | Nov 18 | 2 days | Chee ConleyPresident & CEO | SSale | −134.8K | $0.1998 | −$26.9K | −100.0%0 after | |
| Nov 20, 2024 (view filing)5:00 PM ET | Nov 18 | 2 days | Haas JasonChief Financial Officer | SSale | −137.8K | $0.2103 | −$29.0K | −100.0%0 after | |
| Sep 12, 2024 (view filing) | Sep 10-12 | 2 days | Haas JasonChief Financial Officer | PPurchase | +100.0K | $1.61 | +$161.5K | +407.3%124.6K after | 3 lots |
| Sep 12, 2024 (view filing) | Sep 10-11 | 2 days | Chee ConleyPresident & CEO | PPurchase | +100.0K | $1.61 | +$161.0K | +444.4%122.5K after | 2 lots |
| Jul 2, 2024 (view filing) | Jun 28 | 4 days | Young Richard ADirector | SSale | −34.8K | $5.12 | −$178.4K | −81.3%8.00K after | 10b5-1 |
| Apr 5, 2024 (view filing) | Apr 3 | 2 days | Roth DavidChief Medical Officer | SSale | −10.5K | $4.95 | −$51.7K | −100.0%0 after | 10b5-1 |
| Apr 2, 2024 (view filing) | Apr 2 | Same day | Roth DavidChief Medical Officer | SSale | −150 | $4.98 | −$747 | −1.4%10.5K after | 10b5-1 |
| Dec 26, 2023 (view filing) | Dec 21 | 5 days | Akkaraju SrinivasDirector | PPurchase | +905.0K | $4.42 | +$4.00M | +102.7%1.79M after | |
| Dec 14, 2023 (view filing) | Dec 12 | 2 days | Roth DavidChief Medical Officer | SSale | −6.29K | $4.95 | −$31.1K | −100.0%0 after | 10b5-1 |
| Dec 8, 2023 (view filing) | Dec 6 | 2 days | Roth DavidChief Medical Officer | SSale | −6.29K | $3.95 | −$24.8K | −50.0%6.29K after | 10b5-1 |
| Aug 2, 2023 (view filing) | Jul 31 | 2 days | Roth DavidChief Medical Officer | SSale | −7.35K | $3.95 | −$29.0K | −100.0%0 after | 10b5-1 |
| Jul 18, 2023 (view filing) | Jul 17 | 1 day | Olson Eric RChief Scientific Officer | SSale | −689 | $3.50 | −$2.41K | −9.4%6.66K after | 10b5-1 |
| Oct 3, 2022 (view filing) | Sep 29-30 | 4 days | Tyson TimothyDirector | PPurchase | +16.9K | $6.26 | +$106.0K | +211.6%24.9K after | 2 lots |
| Jan 6, 2022 (view filing) | Jan 5 | 1 day | Olson Eric RChief Scientific Officer | SSale | −2.21K | $3.47 | −$7.66K | −100.0%0 after | |
| Jul 1, 2021 (view filing) | Jul 1 | Same day | Olson Eric RChief Scientific Officer | SSale | −1.16K | $5.55 | −$6.46K | −100.0%0 after |